Immune Protocol
LL-37Complete Dosing & Administration Guide
Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers
Dose Range
0.5-1.6mg/mL (topical)
Frequency
Once daily
Route
Topical application (wound healing)
Cycle Length
12+ weeks
Dosing
How much
do I take?
Starting Dose
0.5 mg/mL topical application
Apply LL-37 solution directly to wound bed after gentle cleansing. Cover with appropriate wound dressing. This concentration demonstrated the strongest efficacy in Phase I/IIa clinical trials for venous leg ulcers, with a 6-fold healing rate increase over placebo. Begin with every-other-day application to assess local tolerability before advancing to daily use.
Standard Dose
0.8 mg/mL topical application
Standard clinical protocol based on Phase I/IIa dose-finding results. Apply to wound bed daily after cleansing, using sterile application technique. The peptide provides both antimicrobial clearance of wound bioburden and pro-healing effects through FPRL1-mediated angiogenesis and keratinocyte migration. Monitor wound healing progression weekly with photographic documentation.
Advanced Dose
1.6 mg/mL topical application
Highest concentration tested in Phase I/IIa trials. Well-tolerated with no serious adverse events at this dose. Reserved for refractory wounds that have not responded to lower concentrations. The higher concentration provides enhanced antimicrobial activity and anti-biofilm effect for heavily colonized or biofilm-associated wounds. Clinical supervision recommended for extended treatment courses.
Timing
Best time to take
Apply LL-37 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, LL-37 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
LL-37 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Administration
How do I
use it?
Reconstitution
What you need
- •LL-37 in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
LL-37 is administered Topical application (wound healing)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your LL-37 formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.
LL-37 safety derives from extensive basic research in immunology and dermatology journals (Nature Immunology, Journal of Immunology) demonstrating antimicrobial activity, wound healing promotion, and immune modulation without systemic toxicity. Human clinical data are limited—most applications remain in vitro or preclinical. Phase 1 safety and pharmacokinetics data suggest good tolerability, but Phase 2+ efficacy trials in infectious disease and skin conditions are ongoing. The peptide is generally recognized as safe for topical and research applications.
Common Side Effects
Experienced by some users
Local site irritation
Mild redness, warmth, or irritation at the wound application site. This is the most frequently reported adverse effect in clinical trials and reflects the peptide's interaction with wound-bed tissues.
Management: Generally self-limiting. If irritation is significant, reduce application frequency to every other day. Ensure wound is gently cleansed before application.
Transient stinging or burning
Brief stinging or burning sensation upon application to open wound surfaces, typically lasting seconds to minutes.
Management: Allow reconstituted solution to reach room temperature before application. Sensation typically diminishes with subsequent applications as wound healing progresses.
Mild perilesional erythema
Redness in the skin surrounding the treated wound area, reflecting local immune activation and increased blood flow from LL-37-induced angiogenesis.
Management: Usually indicates active healing response. Monitor for signs of infection versus expected inflammatory healing. Should remain localized and non-spreading.
Increased wound exudate
Temporary increase in wound fluid production during initial treatment phase as antimicrobial and pro-healing mechanisms activate.
Management: Use appropriate absorbent wound dressings. Typically normalizes within 1-2 weeks as healing progresses and bacterial bioburden is reduced.
Less Common
- •Allergic contact reaction
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with LL-37
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
LL-37 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !High-concentration saline solutions — elevated salt concentrations can reduce LL-37 antimicrobial activity through charge shielding effects - Use with caution—discuss with your healthcare provider.
- !Anionic surfactants or dressings — may bind and inactivate the cationic LL-37 peptide through electrostatic complexation - Use with caution—discuss with your healthcare provider.
- !Serum-rich wound environments without dose adjustment — serum proteins can partially sequester LL-37 and reduce effective concentration - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside LL-37. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Want the Full Picture?
View the complete LL-37 research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.
View Full LL-37 Profile